Available Sessions:
June 21, 2010 12:00 PM ET
Sponsors:
This program is jointly sponsored by the University of Michigan Medical School and IMPACt, Inc.
Commercial Support:
This activity is supported by educational grants from Eli Lilly and Genentech.
Description:
"Virtual Breast Tumor Board" is a case-based discussion that focuses on current issues and changing dynamics in the treatment of patients with triple-negative breast cancer. The panel of experts will discuss the most appropriate management options for the cases as well as recent and on-going clinical trials. In addition, this activity will review important data presented at the 2010 ASCO meeting as it relates to triple-negative breast cancer.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Describe the pathophysiology, natural history and prognosis of patients with triple-negative breast cancer
- Describe the associations between BRCA mutation, basal-like histology and triple-negative breast cancer
- Evaluate currently available treatment options for patients with triple-negative breast cancer
- Discuss recently completed and ongoing research into treatments for triple-negative breast cancer including cytotoxic therapy, epothilones, PARP inhibitors and other targeted agents
- Describe the cell signaling pathways being investigated as targets for triple-negative breast cancer treatments
- Summarize important data on the treatment of triple-negative breast cancer presented at the 2009 San Antonio Breast Cancer Symposium (2009 SABCS)
Target Audience:
This activity has been designed to meet the educational needs of medical, radiation and surgical oncologists involved in the care of patients with breast cancer.
Accreditation Statement:
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Michigan Medical School and IMPACT, Inc. The University of Michigan Medical School is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation:
The University of Michigan Medical School designates this activity for a maximum of 1 AMA PRA Category 1 Credit TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Agenda:
Introduction – Program Course Director
Case Studies – Panel
For each case, the patient history, staging and location of tumor are presented. The panel then discusses the appropriate treatment course for the particular case. Cases will be selected to illustrate the stated learning objectives as they relate to triple-negative breast cancer.
2010 ASCO Update
Q&A
Summary and Conclusions
Faculty:
Tiffany A. Traina, MD, Course Director
Assistant Attending Physician
Breast Cancer Medicine Service
Department of Medicine
Memorial Sloan-Kettering Cancer
Assistant Professor in Medicine
Weill Cornell Medical College
Mark E. Robson, MD
Clinic Director
Clinical Genetics Service
Memorial Sloan-Kettering Cancer Center
Antoinette R. Tan, MD
Assistant Professor of Medicine
Breast Medical Oncology and Phase I Program
The Cancer Institute of New Jersey
University of Michigan CME Content Reviewer
Samuel M. Silver, MD
Professor and Associate Dean for Research
University of Michigan Medical School
Director, University of Michigan Cancer Center Network
University of Michigan Healthcare Network
Disclosure of Conflicts of Interest:
The University of Michigan Medical School endorses the Standards of the Accreditation Council for Continuing Medical Education and the Guidelines of the Association of American Medical Colleges that the sponsors of continuing medical education activities and the speakers at these activities disclose significant relationships with commercial companies whose products are discussed in educational presentations. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Significant relationships exist with the following companies whose products will be discussed.
Tiffany A. Traina, MD
Consultant/Advisory Board: Genentech
Grant/Research: AstraZeneca, Genentech, GlaxoSmithKline, and Roche
Mark E. Robson, MD
Consultant: Pfizer
Grant/Research: Kudos Pharmaceuticals, AstraZeneca
Samuel M. Silver, MD, PhD
Consultant: Blue Cross Blue Shield of Michigan
Grant/Research: Blue Cross Blue Shield of Michigan
All of the following speakers have informed OCME that they have no relationships with companies whose products will be discussed.
Antoinette R. Tan, MD